Genentech, Inc.

F. Hoffmann-La Roche Ag

Array Biopharma Inc.

Piramed Limited

Simon Mathieu

Janet Gunzner

Bing-Yan Zhu

Daniel P Sutherlin

Alan G Olivero

Adrian Folkes

Georgette M Castanedo

Sally Oxenford

Irina Chuckowree

Richard A Goldsmith

Nan Chi Wan

Tim Heffron

Tracy Bayliss

Shumei Wang

Steven T Staben

Joachim Rudolph

Kimberly Malesky

Vickie H Tsui

Jennafer Dotson

Alexandre Joseph Buckmelter

Li Ren

David A Moreno

Ellen Ruth Laird

Bainian Feng

Christian Wiesmann

Wendy B Young

Wendy Lee

James John Crawford

Brad Newhouse

Stephen Joseph Shuttleworth

Jonas Grina

Zhaoyang Wen

Tim Hancox

Stephen Shuttleworth

Ignacio Aliagas-Martin

Steven Mark Wenglowsky

Kateri Ahrendt

Hongqi Tian

Kateri A Ahrendt

Joshua D Hansen

Kim Malesky

Jason De Meese

Paul Lunghofer

Janet Gunzer-Toste

Janet L Gunzner

Christian Weismann

Jeongbeob Seo

Irina Cchuckowree

Janet Gunzer

Bing-Yang Zhu

Compounds of Formulae Ia, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pharmaceutical compounds

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and Ris a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Phosphoinositide 3-kinase inhibitor compounds and methods of use

Compounds having the formula I wherein A, R, R, R, R, R, R, R, R, R, R, R, X, X, Xand n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders. 

Serine/threonine kinase inhibitors

Compounds of Formulae Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Compounds having the formula I wherein A, Z, R, R, R, R, R, R, R, R, R, R, R, Rand n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders. 

Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrazole [3, 4-B] pyridine Raf inhibitors

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Raf inhibitor compounds and methods of use thereof

Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Thiazolopyrimidine PI3K inhibitor compounds and methods of use

Growing community of inventors

South San Francisco, CA, United States of America

Simon Mathieu